Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Maryland Reports First H1N1 Flu-Related Death, USA
An elderly Baltimore metro area resident with serious underlying medical conditions and a novel H1N1 influenza virus infection has died, according to the Department of Health and Mental Hygiene (DHMH). Among other complications, H1N1 flu was a contributing factor, making this Maryland"s first death confirmed to be associated with the novel flu strain. Personal details about the case, including specific underlying health conditions, will not be released to protect the privacy of the resident and the resident"s family.
generic viagra online
Government Of Canada Acts To Help Ensure Soft Vinyl Toys, Child-Care Articles And Other Consumer Products Are Safer
The Honourable Leona Aglukkaq, Minister of Health, announced today that the Government of Canada is proposing new regulations to prevent the use of six chemicals (phthalates) in soft vinyl toys and child-care articles. Regulations are also being proposed to further reduce lead limits in consumer products.
News of the day
PharmaCom BioVet, Inc. Begins To Review The Process To Potentially Receive Minor Use/Minor Species Drug Approval From FDA
PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce that the Company has begun the process to potentially apply and endeavor to receive a Minor Use/Minor Species (MUMS) drug approval from the Federal Drug Administration (FDA). Meeting the MUMS requirement is part of the New Drug Approval Process if the Company decides to potentially run clinical trials on a histone deacetylase inhibitor for canines with hemangiosarcoma, which the Corporation is considering the development of. The histone deacetylase inhibitor would be directed for dogs suffering from an acute type of cancer, canine hemangiosarcoma. The Minor Use and Minor Species Animal Health Act became law in 2004.
Oncology

Stellar Pharmaceuticals Inc. Announces Watson Pharma, Inc. Has Received A Conditional IDE Approval For Stellar's Uracyst(R) From The FDA

Stellar Pharmaceuticals Inc. ("Stellar" or the "Company") (OTCBB:SLXCF) is pleased to announce that its United States licensee, Watson Pharma, Inc. ("Watson") (NYSE:WPI), has received a conditional approval of their Investigational Device Exemption (IDE) to conduct clinical work with Uracyst® from The Food and Drug Administration (FDA) in the United States of America ("USA"). This will allow Watson to continue to move their Uracyst® development program forward towards the eventual approval for the sale of Uracyst® in USA. The conditional approval allows Watson to begin a blinded, placebo-controlled, pilot clinical trial in 100 subjects at 20 clinical study centers in the USA. Peter Riehl, Stellar"s President and CEO stated, "We are very pleased to see another important milestone completed by Watson as they continue to make progress towards the sale of Uracyst® in the largest pharmaceutical market in the world. Stellar is fortunate to have a partner as experienced as Watson is in the field of urology to develop the clinical program for the Uracyst marketing approval in the USA." Stellar


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009